Latest news with #CrisprTherapeuticsAG
Business Insider
30-05-2025
- Business
- Business Insider
Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
In a report released on May 20, Salim Syed from Mizuho Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $85.00. The company's shares opened today at $37.00. Confident Investing Starts Here: Syed covers the Healthcare sector, focusing on stocks such as Vaxcyte, Wave Life Sciences, and Cytokinetics. According to TipRanks, Syed has an average return of -9.6% and a 35.89% success rate on recommended stocks. Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $67.63, an 82.78% upside from current levels. In a report released yesterday, Citizens JMP also reiterated a Buy rating on the stock with a $86.00 price target. CRSP market cap is currently $3.39B and has a P/E ratio of -8.19. Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year. Most recently, in February 2025, John Greene, a Director at CRSP bought 7,000.00 shares for a total of $313,880.00.
Yahoo
21-05-2025
- Business
- Yahoo
Crispr Therapeutics call volume above normal and directionally bullish
Bullish option flow detected in Crispr Therapeutics (CRSP) with 2,899 calls trading, 1.4x expected, and implied vol increasing almost 2 points to 61.27%. Jun-25 30 calls and Oct-25 40 calls are the most active options, with total volume in those strikes near 910 contracts. The Put/Call Ratio is 0.14. Earnings are expected on August 5th. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on CRSP: Disclaimer & DisclosureReport an Issue Strategic Growth and De-risking: Gil Blum's Buy Rating on Crispr Therapeutics AG Promising Potential of Crispr Therapeutics AG: Buy Rating Backed by Strategic Partnership and Diversified Pipeline Crispr Therapeutics AG: Strategic Advancements and Growth Potential Drive Buy Rating Buy Rating for CRISPR Therapeutics: Strategic Collaboration with Sirius Therapeutics to Enhance Pipeline and Capture Anticoagulant Market Share Strategic Expansion and Promising Ventures Drive Buy Rating for Crispr Therapeutics AG
Bloomberg
30-01-2025
- Health
- Bloomberg
NHS Rolls Out £1.7 Million Gene Therapy for Sickle Cell Disease
One of the world's most expensive medicines will be used to treat some patients with sickle cell disease in England using the state-funded National Health Service. The one-time gene-editing therapy Casgevy, developed by Vertex Pharmaceuticals Inc. and Crispr Therapeutics AG, has a list price of £1.7 million ($2.1 million), but England's drug cost regulator said it has negotiated a lower, undisclosed price.
